© Springer International Publishing Switzerland 2015Varsha Gandhi, Kapil Mehta, Rajesh Grover, Sen Pathak and Bharat B. Aggarwal (eds.)Multi-Targeted Approach to Treatment of Cancer10.1007/978-3-319-12253-3_3 3. Chronic Lymphocytic Leukemia at the Genomic Level Hima V. Vangapandu1, 2 and Varsha Gandhi1, 2, 3 (1)…
Fig. 5.1 TAM in modulating cancer-related inflammation. TAM participate in many aspects of cancer growth and progression. More in details, they sustain tumor growth through the release of growth factors,…
Fig. 9.1 (a) Feedback loops of the PI3K/Akt/mTOR pathway. Red line means inhibition and black activation; in blue: PI3k/Akt/mTOR pathway; in brown: MAPK pathway. (b) Two ways of blocking the…
Fig. 8.1 Chemical structures of sirolimus (a), temsirolimus (b), everolimus (c), and ridaforolimus (d) [4] Rapalogs retain the basic structure of the parent rapamycin compound, but differ by the moiety…
Fig. 12.1 The PI3K pathway and associated inhibitor classes. Schematic representation of the PI3K/Akt/mTOR pathway (red) and the MAPK pathway (blue) including recognized points of crosstalk between the respective cascades….
Fig. 10.1 Oncogenic activation of mTOR may be related to multiple oncogenic activations, mutations of major anti-oncogenes as well as microenvironment-dependent parameters such as hypoxia and nutrient depletion Knowing how…
Fig. 2.1 mTOR signaling pathway (detailed in text) 2.2.1.1 mTORC1 mTORC1 includes two unique binding partners: regulatory associated protein of mTOR (Raptor), which recognizes mTOR substrates through their TOR Signaling…
Clinical characteristic Diagnosis Major features Facial angiofibromas or forehead plaque Definite TSC: Either 2 major features or 1 major features plus 2 minor features Probable TSC: One major plus 1…
Fig. 13.1 mTOR complex 1 (mTORC1) signaling aging, longevity, and cancer. (a) Indicated above are stimuli that mTORC1 integrates in the execution of its cell autonomous functions. In a replete…
Agent Phase Clinical trial no. Number of patients Objective response rate (ORR, %) Progression-free survival (PFS) Overall survival (OS) Reference Temsirolimus 2 NCT00087074 41 5 2 months – median time…
